Skip to main content

DataMeds AI, Inc.

corporate_fare Company Profile

DataMeds AI, Inc.

MEDS·NASDAQ·Trade & Services·CIK 0002030763

DataMeds AI, Inc. is a holding company incorporated in 2022, focused on pharmaceuticals and healthcare services. The company aims to create a micro health ecosystem by integrating a pharmacy, wholesale operations, and a technology division that offers a novel platform for hub and clinical services. DataMeds AI, Inc. seeks to improve patient lives and provide solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its patient-centric approach and innovative healthcare applications are designed to shift pharmaceutical care to revolve around the patient across various therapeutic conditions. The company offers a full spectrum of integrated solutions by leveraging its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products, from "specialty-lite" to general maintenance conditions. DataMeds AI, Inc. operates through two wholly owned subsidiaries: Wood Sage LLC and Wellgistics, LLC, and two indirect subsidiaries: Alliance Pharma Solutions LLC d/b/a DelivMeds (now Wellgistics Tech & Hub, LLC) and Community Specialty Pharmacy, LLC (now Wellgistics Pharmacy). In January 2023, the company entered into a Membership Interest Purchase Agreement for the acquisition of Wood Sage, which was completed on June 16, 2024. The acquisition involved paying Mr. Panchal approximately $400,000 in common stock issued at a 20% discount. Wood Sage, a Florida limited liability company formed on June 27, 2014, had no operations to date. In August 2023, Wood Sage acquired 100% of the outstanding membership interests of DelivMeds and Wellgistics Pharmacy.

DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 24 items for MEDS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • DataMeds AI Reports Q2 Revenue Beat, $18.4M Loss, and $6.5M Funding
  • DataMeds AI Reports $26.1M Loss, Going Concern Doubt, and Nasdaq Equity Deficiency
  • DataMeds AI Registers 34.5M Shares for Resale — Potential 92% Dilution from May 2026 Toxic Convertible Deal
  • DataMeds AI Inks LOI for Transformative Reverse Merger with EOS, Scilex, Datavault, and HBA

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$23.34M
Net Income
-$101.27M
Diluted EPS
-$1.43
Op. Cash Flow
-$10.86M
Gross Profit
-$6.43M
Operating Income
-$93.75M
Cash & Equivalents
$42.57K
Total Debt
$23.49M
Debt / Equity
-1.89×
Net Margin
-433.9%
Shares Outstanding
101.31M sh
Source: 10-K · filed 2026-04-24 · accession 0001493152-26-018958
$1.55 +15.67% today
52-week range · as of 2026-11-16 $0.5525 – $35.5
Market cap
$7.66M
Volume
94.2M (17.4× avg)
3-mo avg 5.4M
Live data · 2026-11-22 07:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MEDS - Filings & News (Page 2)

MEDS
Aug 18, 2026, 7:43 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.50
Real-time Price: $1.55 info
Change: +$0.050 (+3%) info
Market Cap: $7.662M info
MEDS
Aug 17, 2026, 6:05 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.50
Real-time Price: $1.55 info
Change: +$0.050 (+3%) info
Market Cap: $7.662M info
MEDS
Aug 07, 2026, 5:23 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $2.01
Real-time Price: $1.55 info
Change: -$0.460 (-23%) info
Market Cap: $7.662M info
MEDS
Aug 04, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.17
Real-time Price: $1.55 info
Change: -$1.62 (-51%) info
Market Cap: $7.662M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets